Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Recently I was hospitalized for A-fib, and a nodule was seen on the myocardial perfusion scan CT. It was in the right middle lobe, and 0.9 x 0.5 cm in...
Was dx poorly differentiated adeno mets in bones in February 2018. Just completed 4 cycles Carbo Alimta Avastin. Booked pet scan and brain mri for 21...
Hi, My father has had a recent diagnose of lung cancer and because he lives in Jamaica and I am concerned about him receiving the best medical...
Firstly, having looked at this forum in the past, I am in awe of the knowledge, courage and empathy of those that use and support it. So to my...
Hi! My 74 year old mom was diagnosed with small cell lung cancer in September 2017 and she has been on chemotherapy since then. The main tumor is...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.